nach oben

Erschienen in:

01.10.2014 | Research Article

A novel FGF2 antagonist peptide P8 with potent antiproliferation activity

verfasst von: Lei Fan, Hang Xie, Lingzi Chen, Hui Ye, Shilong Ying, Cong Wang, Xiaoping Wu, Wulan Li, Jianzhang Wu, Guang Liang, Xiaokun Li

Erschienen in: Tumor Biology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Some fibroblast growth factors (FGFs) play a critical role in tumorigenesis and progression. Among them, FGF2 was highly expressed in some tumors, and antagonists binding to FGF2 can suppress the growth of tumor cells. Therefore, FGF2 has been considered as an important target in cancer therapy. In this study, we identified a novel FGF2-binding short peptide (P8, PLLQATAGGGS-NH₂) using phage display technology and alanine scanning. The P8 peptide suppressed FGF2-induced proliferation with no cytotoxic effect on cells, arrested the cycle at the G0/G1 phase in B16-F10 cells, and downregulated the activation of fibroblast growth factor receptor substrate 2α (FRS2α)/ERK cascade in B16-F10, NIH-H460, and SGC-7901 cells. Besides, P8 peptide can also inhibit the phosphorylation of FRS2α stimulated by FGF1 and KGF2. These implied that P8 peptide may develop as a multi-target antagonist peptide contributing to tumor treatment.

Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7:165–97.CrossRefPubMed

Goldfarb M. Fibroblast growth factor homologous factors: evolution, structure, and function. Cytokine Growth Factor Rev. 2005;16:215–20.PubMedCentralCrossRefPubMed

Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.CrossRefPubMed

Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28–39.CrossRefPubMed

Shi HL, Yang T, Deffar K, Dong CG, Liu JY, Fu CL, et al. A novel single-chain variable fragment antibody against FGF-1 inhibits the growth of breast carcinoma cells by blocking the intracrine pathway of FGF-1. IUBMB Life. 2011;63:129–37.PubMed

Wang C, Yu Y, Li Q, Gao S, Jia X, Chen X, et al. P7 peptides suppress the proliferation of K562 cells induced by basic fibroblast growth factor. Tumour Biol. 2012;33:1085–93.CrossRefPubMed

Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell. 2007;12:572–85.PubMedCentralCrossRefPubMed

Chung SS, Koh CJ. Bladder cancer cell in co-culture induces human stem cell differentiation to urothelial cells through paracrine FGF10 signaling. In Vitro Cell Dev Biol Anim. 2013;49:746–51.PubMedCentralCrossRefPubMed

Facchiano A, Russo K, Facchiano AM, De Marchis F, Facchiano F, Ribatti D, et al. Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. J Biol Chem. 2003;278:8751–60.CrossRefPubMed

10.

Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 2007;13:2025–44.CrossRefPubMed

11.

Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle. 2009;8:580–8.CrossRefPubMed

12.

Cochran S, Li C, Fairweather JK, Kett WC, Coombe DR, Ferro V. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem. 2003;46:4601–8.CrossRefPubMed

13.

Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 1994;54:2654–60.PubMed

14.

Danesi R, Del B, Soldani P, Campagni A, La Rocca R, Myers C, et al. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer. 1993;68:932–8.PubMedCentralCrossRefPubMed

15.

Sola F, Moneta D, Ubezio P, Grandi M. The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule. Cancer Chemother Pharmacol. 1999;43:241–6.CrossRefPubMed

16.

Wu J, Liang G, Wu X, Yang S, Li X. Progress of inhibitors targeting fibroblast growth factor. Chem Online. 2010;73:140–6.

17.

Manetti F, Corelli F, Botta M. Fibroblast growth factors and their inhibitors. Curr Pharm Des. 2000;6:1897–924.CrossRefPubMed

18.

Fan H, Zhou H, Li W. The interaction of fibroblast growth factor/fibroblast growth factor receptor and FGF inhibitors. Prog Biochem Biophys. 2001;28:338–41.

19.

Wu X, Yan Q, Huang Y, Huang H, Su Z, Xiao J, et al. Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med. 2010;14:351–6.PubMedCentralCrossRefPubMed

20.

Wang C, Lin S, Nie Y, Jia X, Wang J, Xiao J, et al. Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells. Cancer Sci. 2010;101:1212–8.CrossRefPubMed

21.

Yu Y, Gao S, Li Q, Wang C, Lai X, Chen X, et al. The FGF2-binding peptide p7 inhibits melanoma growth in vitro and in vivo. J Cancer Res Clin Oncol. 2012;138:1321–8.CrossRefPubMed

22.

Victoria K, Simon J. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther. 2010;125:105–17.CrossRef

23.

Wang R, Luo W, He D, Wu J, Zhu G, Tan X, et al. Inhibition of proliferation of non-small cell lung cancer cells by a FGF antagonist peptide. Int J Pept Res Ther. 2014;20:109–15.CrossRef

24.

Wu X, Huang H, Wang C, Lin S, Huang Y, Wang Y, et al. Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation. Oncotarget. 2013;4:1819–28.PubMedCentralPubMed

25.

Smalley K. A pivotal role for erk in the oncogenic behaviour of malignant melanoma? Int J Cancer. 2003;104:527–32.CrossRefPubMed

26.

Nesbit M, Nesbit H, Bennett J, Andl T, Hsu M, Dejesus E, et al. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene. 1999;18:6469–76.CrossRefPubMed

27.

Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine. 2000;12:547–54.CrossRefPubMed

28.

Lefèvre G, Babchia N, Calipel A, Mouriaux F. Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest Ophthalmol Vis Sci. 2009;50:1047–57.CrossRefPubMed

29.

Joseph T, Yuan K, You-Fang S. Cell cycle regulation of astrocytes by extracellular nucleotides and wbroblast growth factor-2. Purinergic Signal. 2005;1:329–36.CrossRef

30.

Pagès G, L’Allemain G, Chambard J, Meloche S. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A. 1993;90:8319–23.PubMedCentralCrossRefPubMed

31.

Dai X, Cai C, Xiao F, Xiong Y, Huang Y, Zhang Q, et al. Identification of a novel afgf-binding peptide with anti-tumor effect on breast cancer from phage display library. Biochem Biophys Res Commun. 2014;445:795–801.CrossRefPubMed

Titel: A novel FGF2 antagonist peptide P8 with potent antiproliferation activity
verfasst von: Lei Fan
Hang Xie
Lingzi Chen
Hui Ye
Shilong Ying
Cong Wang
Xiaoping Wu
Wulan Li
Jianzhang Wu
Guang Liang
Xiaokun Li
Publikationsdatum: 01.10.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 10/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2356-4

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

A novel FGF2 antagonist peptide P8 with potent antiproliferation activity

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials

Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population

Abnormal MGMT promoter methylation may contribute to the risk of esophageal cancer: a meta-analysis of cohort studies

Biological and clinical implications of endocan in gastric cancer

Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review

MicroRNA-27b suppresses growth and invasion of NSCLC cells by targeting Sp1

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie